GLP-1 Shortage Update:
What's Actually Available in March 2026

The headline is good: both semaglutide and tirzepatide shortages have been officially resolved by the FDA. After years of patients struggling to fill prescriptions, calling dozens of pharmacies, and going without medication for weeks at a time, brand-name GLP-1 medications are now substantially more available at retail pharmacies across the United States.

But "available" and "accessible" are different things. The resolution of the shortage has not solved the access problem for most cost-conscious patients — it has merely shifted the nature of the barrier from "physically can't get it" to "can't afford it." Understanding this distinction is crucial for navigating your GLP-1 options in March 2026.

The Brand-Name Picture in March 2026

Ozempic (Semaglutide for Type 2 Diabetes)

Ozempic (0.5mg, 1mg, and 2mg doses) is now generally in stock at major pharmacy chains including CVS, Walgreens, Walmart, and Costco. The sporadic shortages that characterized 2022-2024 have largely resolved. Patients with type 2 diabetes who qualify for Ozempic can typically get it filled without the multi-pharmacy calling that was necessary at the shortage peak.

Insurance coverage for Ozempic remains strong for patients with type 2 diabetes — it's typically covered under prescription drug benefits when the indication is diabetes, with copays ranging from $0-50/month depending on the plan. Novo Nordisk's patient assistance programs remain active for uninsured patients who meet income criteria.

Wegovy (Semaglutide for Obesity)

Wegovy supply has improved dramatically from the severe shortages of 2022-2023. All doses (0.25mg through 2.4mg) are now generally available. However, insurance coverage for Wegovy remains the critical challenge. Most commercial insurance plans still do not cover anti-obesity medications, and Medicare Part D coverage under the Inflation Reduction Act provisions for weight management has had limited implementation. Wegovy without insurance costs approximately $1,349/month — a price point that puts it out of reach for most patients paying cash.

Mounjaro (Tirzepatide for Type 2 Diabetes)

Mounjaro availability has similarly normalized across doses. Insurance coverage patterns are similar to Ozempic — good coverage for type 2 diabetes indication, limited for obesity-only.

Zepbound (Tirzepatide for Obesity)

Zepbound — tirzepatide specifically approved for obesity — is now broadly available. The vial formulation (introduced as a lower-cost option in 2024) remains available through Eli Lilly's LillyDirect program at a lower price point than the pen formulation, though still expensive for cash-pay patients. Eli Lilly's savings programs have made Zepbound more accessible for some commercially insured patients.

Why "Shortage Resolved" Doesn't Fix the Access Problem

Here's the reality check: even with both shortages resolved, the number of Americans who can afford brand-name GLP-1 medications at list price without insurance remains a small fraction of those who could benefit from them.

What the Shortage Resolution Means for Compounded GLP-1s

This is where the story gets complicated for patients who have been relying on compounded GLP-1 medications. The shortage resolution directly affected the legal framework for compounding — here's the practical impact:

What Changed After Shortage Resolution

As covered in our legal status article, the shortage resolution ended the blanket exception that allowed 503B outsourcing facilities to bulk-compound semaglutide and tirzepatide. The market contracted. Some providers exited. Some pharmacies stopped offering these medications. The patient experience in accessing compounded GLP-1s became more variable across providers.

What Didn't Change

The fundamental access math still works. Compounded semaglutide from a licensed 503A pharmacy with physician oversight still costs $179-299/month compared to $1,349 for Wegovy. For the patient who can't afford brand-name and doesn't have insurance coverage, compounded alternatives remain the only realistic pathway to treatment.

The providers who weathered the regulatory transition are, in many ways, the stronger providers — they invested in compliance infrastructure, legal review, and proper pharmacy partnerships to continue operating. The fly-by-night operations that used the shortage as cover to cut corners have largely been driven out of the market by FDA enforcement.

The Market in March 2026

As of March 2026, the compounded GLP-1 market is smaller than its 2023-2024 peak but still substantial. Multiple licensed telehealth providers continue offering physician-supervised programs with accredited pharmacy partners. The patient experience — from consultation to delivery — has generally improved as providers have professionalized their operations.

What About Generic GLP-1s? The 2027 Horizon

One of the most frequently asked questions: when will generic GLP-1 medications be available? The answer is: not yet, but the timeline is getting clearer.

Novo Nordisk's core patents on semaglutide are scheduled to expire between 2026 and 2032, depending on the specific formulation and market. The first generic semaglutide applications from Chinese and Indian manufacturers are beginning the FDA review process. Most analysts project that FDA-approved generic semaglutide (similar to the Ozempic/Wegovy formulation) will not be commercially available in the US before 2027-2028 at the earliest, and the real commercial launch that drives significant price competition may be 2029-2030.

Canadian generics — which have been available in some form in Canada — are not legally importable into the US for individual use under current FDA policy.

The bottom line: the generic GLP-1 era is coming, but it is still 2-4 years away for most US patients. In the meantime, compounded GLP-1s from licensed providers remain the primary affordability option for cost-conscious patients who don't have insurance coverage.

Practical Advice for Navigating Access in March 2026

Whether you're newly starting or an existing patient whose previous provider changed its practices, here's current practical guidance:

• Check your insurance first. Insurance coverage for anti-obesity medications has been slowly improving, driven partly by the Treat and Reduce Obesity Act and commercial plan pressure. It's worth calling your insurer directly — coverage may have changed since you last checked.
• Check manufacturer assistance programs. Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) both have patient assistance programs for uninsured or underinsured patients meeting income criteria. These can bring costs to $0-99/month for eligible patients.
• Consider compounded alternatives. If brand-name is unaffordable and you don't qualify for manufacturer assistance, licensed compounded programs remain a legal and affordable option. Use our comparison tool to find currently operating providers.
• Be wary of "deals" that seem too good. Post-shortage enforcement has pushed some providers underground. Offers of compounded GLP-1s without physician prescriptions, from social media sellers, or at implausibly low prices are significant red flags.

Looking Ahead: The 2026-2027 Access Outlook

The outlook for GLP-1 access is genuinely improving, though "improving" doesn't mean "solved." Here are the positive developments to watch:

• Congressional action on Medicare coverage: The Treat and Reduce Obesity Act has been introduced in multiple sessions; passage would significantly expand Medicare coverage for anti-obesity medications.
• Employer plan expansion: Large employers are increasingly adding GLP-1 coverage to employee health plans, recognizing the long-term cost savings from treating obesity. Employer-sponsored coverage is expected to continue growing in 2026-2027.
• Oral semaglutide availability: Novo Nordisk is pursuing approval for oral semaglutide (a pill form) for obesity at a target price point lower than injectable. If approved and priced competitively, this could significantly expand access.
• Competition from new entrants: As additional GLP-1 agonists complete trials and reach market, competition will eventually drive prices down — though this effect may not be significant until 2027-2028.